umifenovir (arbidol) in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Nojomi, 2020 0.49 [0.04; 5.58]
Nojomi, 2020 (REV) 0.49 [0.04; 5.58]
0.49 [0.09 ; 2.74 ] Nojomi, 2020, Nojomi, 2020 (REV) 2 0% 200 moderate not evaluable clinical deteriorationdetailed results ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
0.86 [0.06 ; 11.36 ] ELACOI (Standard of care), 2020 1 0% 23 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
0.18 [0.01 ; 3.99 ] ELACOI (Standard of care), 2020 1 0% 21 NA not evaluable radiologic improvement (7-day)detailed results ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
0.08 [0.00 ; 1.71 ] ELACOI (Standard of care), 2020 1 0% 21 NA not evaluable viral clearance detailed results ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
2.80 [0.31 ; 25.53 ] ELACOI (Standard of care), 2020 1 0% 23 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
2.10 [0.60 ; 7.35 ] ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020 2 0% 92 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
0.98 [0.41 ; 2.35 ] ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020 2 0% 92 moderate not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-30 12:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 516
- roots T: 290